RxDoctor Payments Data

Joseph Piperato, MD

Internal Medicine · Miami, FLNPI 1699731604

Payments from drug & device makers

$45,385in general payments, 2019–2025

Across 547 payments — averaging $82.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$25K
  • Viiv Healthcare Company$16K
  • Theratechnologies Inc.$798
  • Merck$550
  • Johnson & Johnson$488
  • EMD Serono, Inc.$338
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$11,96026%
  • Speaking & faculty fees$18,91642%
  • Travel & lodging$3,0717%
  • Food & beverage$11,17725%
  • Education$2601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,385 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$48,145
Medicare patients
99
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala506$2,052,002
RukobiaFostemsavir Tromethamine67$589,603
TriumeqAbacavir/Dolutegravir/Lamivudi118$454,390
TivicayDolutegravir Sodium163$396,118
GenvoyaElviteg/Cob/Emtri/Tenof Alafen83$338,165
JulucaDolutegravir/Rilpivirine87$321,550
DescovyEmtricitabine/Tenofov Alafenam136$312,629
Egrifta SvTesamorelin Acetate39$279,613
PrezcobixDarunavir/Cobicistat99$233,605
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$208,781
DovatoDolutegravir Sodium/Lamivudine51$150,224
CabenuvaCabotegravir/Rilpivirine19$108,728
IsentressRaltegravir Potassium39$83,983
Etravirine64$67,813
MounjaroTirzepatide55$66,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$25,396$2,702,796725 claims
Viiv Healthcare CompanyRukobia, Triumeq, Tivicay, Juluca, Dovato$16,071$2,020,615505 claims
Theratechnologies Inc.Egrifta Sv$798$279,61339 claims
Johnson & JohnsonPrezcobix, Xarelto$488$246,114123 claims
Janssen Products, LPSymtuza$130$208,78147 claims
MerckIsentress, Pifeltro, Januvia$550$147,15685 claims
Lilly USA, LLCMounjaro$134$66,81955 claims
PfizerEliquis$127$18,85924 claims
AbbVieRestasis$224$14,83619 claims
Idorsia Pharmaceuticals US IncQuviviq$144$7,11615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →